<DOC>
	<DOCNO>NCT00120510</DOCNO>
	<brief_summary>Anti-HIV treatment consist lamivudine/zidovudine ( 3TC/ZDV ) efavirenz ( EFV ) current standard care initial treatment HIV area world . The purpose study determine best time start anti-HIV treatment treatment-naive adult Haiti .</brief_summary>
	<brief_title>Early Versus Standard Start Anti-HIV Therapy Treatment-Naive Adults Haiti</brief_title>
	<detailed_description>In many part world , initial standard care HIV include 3TC/ZDV non-nucleoside reverse transcriptase inhibitor EFV . However , unclear early ( CD4 count le 350 cells/mm3 ) delayed ( CD4 count le 200 cells/mm3 ) therapy initiation lead improved survival . This study determine appropriate time initiate ART HIV infect individual Haiti . The study enroll patient Haitian Study Group Kaposi 's Sarcoma Opportunistic Infections ( GHESKIO ) Centers . Some participant study active pulmonary tuberculosis ( TB ) . This study last least 3 year . Participants randomly assign one two group study entry . Group A participant receive 3TC/ZDV twice daily EFV daily study enrollment . Participants receive TB therapy time enrollment may observe 2 week prior begin early therapy . Dosage adjustment EFV may necessary participant receive rifampin part TB therapy . Group B participant receive 3TC/ZDV twice daily EFV daily develop clinical AIDS CD4 count drop 200 cells/mm3 ( WHO Stage IV ) . Directly observed therapy use first two month treatment every participant . Group A participants 14 study visit begin treatment ; visit occur Months 1 , 2 , 3 , every 3 month thereafter . Medical medication history , physical exam , contraceptive counseling woman occur visit . HIV counseling , blood collection , HIV stag occur visit . At study visit , Group A participant ask complete quality life adherence questionnaire . Group B participants 14 study visit study entry begin treatment meet WHO criteria . Assessments Group A . Any participant fails first-line regimen study switch second-line ART regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>HIVinfected Received pre posttest counsel GHESKIO Centers CD4 count 200 350 cells/mm3 World Health Organization ( WHO ) Stage I , II , III HIV disease Willing use acceptable form contraception WHO Stage IV HIV disease ( AIDS ) 7 day cumulative ART prior study entry OR ART time study entry Active TB , diagnostic workup TB incomplete OR decision treat TB make . More information criterion find protocol . Recurrent active TB OR history interrupt incomplete TB therapy . More information criterion find protocol . Has evaluate latent TB decision treat latent TB isoniazid make . More information criterion find protocol . Requires ART next 3 month , opinion investigator Other serious medical illness require chronic maintenance therapy ( e.g. , hypertension , diabetes ) UNLESS individual complete least 14 day therapy prior study enrollment AND clinically stable Any psychological condition ( e.g. , severe depression , schizophrenia ) , opinion investigator , may interfere study Any social condition ( e.g. , pending emigration , pending incarceration ) , opinion investigator , may interfere study Active drug alcohol use , opinion investigator , may interfere study Current inflammation pancreas Allergy/sensitivity study drug formulation Requires certain medication Enrolled another therapeutic interventional clinical trial Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>TB</keyword>
</DOC>